Zubrin
Withdrawn
tepoxalin
MedicineVeterinaryWithdrawn
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
The market authorisation for Zubrin has been withdrawn at the request of the marketing-authorisation holder.
Reduction of inflammation and relief of pain caused by acute and chronic musculoskeletal disorders.